Insular-striatal activation during COVID-19 predicts stress reactivity in high-trait anxiety.

Publication date: Feb 12, 2025

The COVID-19 pandemic, unlike natural disasters that cause short-term stress, has led to prolonged psychological strain, increasing attentional biases toward health threats and worsening mental health. Prolonged exposure to pandemic-related stressors has exacerbated these issues, with individual differences, such as anxiety levels, influencing vulnerability and resulting in varied outcomes. Understanding how neurocognitive processes modulate attentional biases, such as prolonged attention (overresponding) to threats or avoidance, is crucial for explaining their effects on mental health during the pandemic. Real-world examination of these biases is needed to confirm their manifestation and better target interventions. This longitudinal study explored the neural network of attentional biases in anxious individuals, focusing on whether initial activation at baseline (T1) could predict changes in perceived stress. High and low trait anxious (HTA, LTA) adults completed an emotional Stroop task during two fMRI visits, one year apart. Results showed insular-fronto-striatal hypoactivation in the HTA group over time, indicating increased avoidance in HTA participants. Initial insular-striatal activation at T1 predicted perceived stress changes in the HTA group. Reduced activation in these regions suggests avoidance and impaired stress coping, highlighting increased stress vulnerability in HTA individuals during the pandemic and underscoring the importance of interventions to enhance resilience.

Open Access PDF

Concepts Keywords
Health anxiety
Neural attentional bias
Pandemic COVID-19
Psychological fMRI
longitudinal

Semantics

Type Source Name
disease MESH COVID-19
disease MESH anxiety
drug DRUGBANK Tropicamide
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH uncertainty
disease MESH infection
drug DRUGBANK Carboxyamidotriazole
disease MESH psychological distress
disease IDO process
disease IDO history
disease IDO quality
disease IDO algorithm
drug DRUGBANK Gonadorelin
drug DRUGBANK Ranitidine
disease MESH psychiatric disorders
disease IDO facility
disease MESH syndrome
disease MESH panic disorders
disease MESH affective disorders
drug DRUGBANK Etoperidone
disease MESH PTSD
disease MESH emergency
disease MESH depression
drug DRUGBANK Atomoxetine
drug DRUGBANK Methylphenidate
disease MESH attention deficit hyperactivity disorder
disease MESH comorbidity
disease MESH anxiety disorder
disease MESH bipolar disorder
disease MESH social anxiety disorder
disease MESH long COVID
pathway REACTOME Sensory Perception
disease MESH alexithymia
pathway KEGG Coronavirus disease
disease MESH Emerging infectious diseases
disease MESH autism spectrum disorder
drug DRUGBANK Huperzine B
disease MESH obsessive compulsive disorder
disease MESH panic
drug DRUGBANK L-Aspartic Acid
disease MESH hypertension
disease IDO symptom
disease MESH childhood trauma
disease MESH Infectious Diseases
drug DRUGBANK Proline
drug DRUGBANK Aspartame
disease IDO intervention

Original Article

(Visited 1 times, 1 visits today)